Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

604 results about "Ethylene glycol toxicity" patented technology

Diethylene glycol has moderate acute toxicity in animal experiments. The LD50 for small mammals has been tested at between 2 and 25 g/kg, less toxic than its relative ethylene glycol, but still capable of causing toxicity in humans.

Neutral blockage removing agent composition used for oil recovery formation in oilfield and preparation method thereof

The invention relates to a neutral blockage removing agent composition used for an oil recovery formation in an oilfield. The neutral blockage removing agent composition is prepared from the following raw materials in parts by weight: 30-36 parts of disodium polyepoxysuccinicate, 18-25 parts of sodium gluconate, 2-3 parts of polyethylene glycol, 2-4 parts of triethanolamine, 9-12 parts of ethyl lactate, 7-10 parts of fatty alcohol polyoxyethylene ether sodium sulfate, 8-12 parts of amino acid sodium, 10-15 parts of activated attapulgite, 0.1-0.2 part of vanadium pentoxide, 5-7 parts of lipase, 5-8 parts of sorbitan fatty acid ester, 15-18 parts of P-hydroxy sodium sulfonate, 3-7 parts of tert-butyl hydroperoxide and 0.1-0.3 part of diethylene glycol monolaurate. The neutral blockage removing agent composition has high blockage removing speed, is neutral, is free of corrosion and can quickly dissolve material scales, asphalt sediment scales, carbonate scales, silicate scales and the like generated by an ASP flooding system; waste liquid for blockage removal can be degraded and does not need to be discharged onto the ground to be subjected to sewage treatment, the formation in the oilfield is cleaned to remove the blockage, no corrosion, dead angle, precipitation or secondary well blockage is generated, and the blockage removal time does not exceed 24 hours.
Owner:GANSU HEIMA PETROCHEM ENG

Tin cobalt alloy/ graphene composite material and preparation method thereof

The invention discloses a tin cobalt alloy / graphene composite material and a preparation method of the tin cobalt alloy / graphene composite material. The preparation method of the tin cobalt alloy / graphene composite material includes the following steps that firstly, graphene oxide is dispersed into methyl alcohol or ethylalcohol or ethylene glycol or diethylene glycol, and then suspension liquid is prepared; secondly, cobalt salt and tin slat of which the mass ratio of the sum of mass to the mass of graphene oxide ranges from 60:1 to 30:1 dissolve in the suspension liquid prepared through the first step, wherein the molar ratio of a cobalt element to a tin element ranges from 1: 0.66 to 1:3; thirdly, a sodium borohydride alcoholic solution of which the concentration ranges from 1 mol / L to 2.5 mol / L is prepared, alcohol used in the first step is used in this step, the sodium borohydride alcoholic solution is mixed with the suspension liquid obtained through the second step, nitrogen is injected, and after 10 minutes of bubbling, solvent heat treatment is conducted, wherein solvent heat treatment refers to the process that a mixture reacts for 6 h to 12 h at the temperature of 100 DEG C to 160 DEG C in a closed reaction kettle and then is cooled to the room temperature, and the molar ratio of the cobalt element in sodium borohydride to the cobalt element in the cobalt salt is 6-13 to 1; fourthly, a sample obtained in the third step is repeatedly washed centrifugally in ethyl alcohol and deionized water, and a product is obtained after vacuum drying.
Owner:CHANGSHA GUORONG NEW ENERGY

Non-flammable topical anesthetic liquid aerosols

A topical liquid aerosol formulation for accurate metered dose delivery has been developed which includes a concentrate comprising a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon (HFC) propellant. In the preferred embodiment, the concentration of the non-alcohol solvent in the concentrate is between about 75% and 85% by weight of the formulation. In the most preferred embodiment, the non-alcohol solvent is a water-soluble polyol such as ethylene glycol, propylene glycol, glycerol, diethylene glycol, dipropylene glycol, oligoalkylene glycols, liquid polyalkylene glycols, or combinations thereof. In one embodiment, the concentration of the local anesthetic in the concentrate is between about 15% and 25% by weight. In the preferred embodiment, the hydrofluorocarbon propellant is 1,1,1,2-tetrafluoroethane 1,1,1,2,3,3,3-heptafluoropropane or combinations thereof, in a concentration between about 35% and 65% by weight of the final formulation, more preferably between about 45% and 55% by weight of the final formulation. A particularly preferred formulation includes benzocaine, tetracaine, and butylaminobenzoate, wherein the concentration of benzocaine in the concentrate is 14% by weight, the concentration of tetracaine in the concentrate is 2% by weight, and the concentration of butylaminobenzoate in the concentrate is 2% by weight. It has been found that the formulation is more stable in the substantial absence of oxygen. The formulation is preferably administered using a metered dose device for release of a controlled amount of the local anesthetic.
Owner:PRECISION DERMATOLOGY

Use of nanoscale particles for improving dirt removal

InactiveUS20060009370A1Increase in hydrophiliaImprove soil removalInorganic/elemental detergent compounding agentsPigmenting treatmentApatitePolyethylene glycol
Soil is removed from cotton and/or a cotton/wool blend material and the resoilability of the material is reduced by a process which comprises contacting the material with a composition comprising nanoscale particles having a particle size of from 5 to 500 nm wherein the particles are comprised of of precipitated silicas, aerogels, xerogels, Mg(OH)2, boehmite (Al(O)OH), ZrO2, ZnO, CeO2, Fe2O3, Fe3O4, SiO2, TiN, hydroxy.apatite, bentoite, hectorite, SiO2:CeO2, SnO2, In2O3:SnO2, MgAl2O4, HfO2, SiO2 Sols, Al2O3 sols, TiO2 sols, and mixtures thereof and a hydrophilizing agent selected from the group consisting of ethanol, n- or i-propanol, butanols, ethylene glycol methyl ether, ethylene glycol ethyl ether, ethylene glycol propyl ether, ethylene glycol mono-n-butyl ether, diethylene glycol methyl ether, diethylene glycol ethyl ether, propylene glycol methyl, ethyl or propyl ether, dipropylene glycol monomethyl or monoethyl ether, diisopropylene glycol monomethyl or monoethyl ether, methoxy, ethoxy or butoxytriglycol, 1-butoxyethoxy-2-propanol, 3-methyl-3-methoxybutanol, propylene glycol t-butyl ether, alcohols, more particularly C1-4 alkanols, glycols and polyols and polyethylene glycol liquid at room temperature, carboxylic acid esters and mixtures thereof.
Owner:ZUECHNER LARS +3
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products